SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 25,972 Shares of Stock

Posted by Brian Himes on Aug 27th, 2026

SiBone (NASDAQ:SIBN – Get Free Report) CEO Laura Francis sold 25,972 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $20.12, for a total value of $522,556.64. Following the completion of the transaction, the chief executive officer owned 291,491 shares of the company’s stock, valued at approximately $5,864,798.92. The trade was a 8.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Laura Francis also recently made the following trade(s):

On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total transaction of $78,538.46.
On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Stock Performance

Shares of SIBN stock opened at $19.43 on Thursday. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89. The business has a 50-day simple moving average of $17.74 and a 200-day simple moving average of $15.40. The stock has a market cap of $861.70 million, a PE ratio of -57.15 and a beta of 0.66.

SiBone (NASDAQ:SIBN – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. On average, equities analysts expect that SiBone will post -0.4 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on SIBN shares. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Truist Financial reissued a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. TD Cowen boosted their price target on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, UBS Group upped their price objective on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.17.

Read Our Latest Stock Report on SIBN

Institutional Trading of SiBone

A number of institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System lifted its holdings in SiBone by 1,751.6% in the 2nd quarter. California State Teachers Retirement System now owns 726,942 shares of the company’s stock valued at $11,864,000 after purchasing an additional 687,681 shares in the last quarter. VELA Investment Management LLC boosted its stake in SiBone by 7.4% during the 2nd quarter. VELA Investment Management LLC now owns 201,094 shares of the company’s stock worth $3,282,000 after purchasing an additional 13,934 shares during the last quarter. Versant Capital Management Inc grew its holdings in shares of SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after buying an additional 887 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of SiBone by 8.7% during the first quarter. Bank of America Corp DE now owns 419,473 shares of the company’s stock worth $5,298,000 after buying an additional 33,688 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of SiBone in the first quarter valued at about $159,000. 98.11% of the stock is owned by institutional investors and hedge funds.

SiBone Company Profile

(Get Free Report)

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.